At a Glance
- Company: Adragos Pharma AG
- Location: Switzerland
- Main headline: 300,000 person‑hours; 150 validations; 250 calibrations
- Focus area: Sterile fill‑finish GMP manufacturing
- Next steps: Final aseptic simulations; resume commercial batches
What happened?
Adragos Pharma received formal Swissmedic approval for its modernised Beta Line sterile manufacturing suite following a 2024/2025 upgrade programme. The Swiss Agency for Therapeutic Products confirmed GMP compliance after a successful October 2025 inspection.
Why does it matter?
The approval validates Adragos’ investments in advanced technologies like Reduced Access Barrier Systems (RABS), enhancing sterile fill‑finish capabilities for contract manufacturing. It positions the site to support client commercial orders amid rising demand for high‑quality sterile production.
Who’s behind it?
Adragos Pharma, a Swiss CDMO, upgraded its Beta Line with 300,000 person‑hours, 150 validation activities, 250 equipment calibrations and 350 updated SOPs. Three customer audits provided positive feedback on readiness.
How was it achieved?
Modernisation focused on future‑proofing manufacturing controls, quality systems and regulatory compliance, culminating in Swissmedic clearance for GMP operations.
What’s next?
Adragos completes final aseptic process simulations before resuming commercial batch manufacturing to fulfil its order book.
What are people saying?
Adragos noted the milestone confirms “the site’s capabilities… after extensive validation and customer audits.”